<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ergotamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ergotamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ergotamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11644" href="/d/html/11644.html" rel="external">see "Ergotamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13275" href="/d/html/13275.html" rel="external">see "Ergotamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708746"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Concurrent drug therapy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine with potent CYP 3A4 inhibitors, including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of ergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Therefore, concomitant use of these medications is contraindicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F166310"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ergomar</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F166343"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimigraine Agent;</li>
<li>
                        Ergot Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F166313"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Contraindicated in patients with coronary artery disease, hypertension, peripheral vascular disease, or renal or hepatic disease, or patients who are pregnant or of childbearing potential. May be associated with significant side effects and may worsen nausea and vomiting associated with migraine. Other migraine-specific agents are preferred; ergotamine may be considered in patients with migraine attacks &gt;48 hours or those with frequent headache recurrence (EHF/WHO [Steiner 2019]; Tfelt-Hansen 2000; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sublingual: </b>2 mg as a single dose; if symptoms persist, may repeat dose after ≥30 minutes. Maximum: 6 mg per 24 hours; 10 mg/week. <b></b></p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991092"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with impaired renal function.</p></div>
<div class="block doha drugH1Div" id="F50988375"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with impaired hepatic function.</p></div>
<div class="block doe drugH1Div" id="F166314"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Not recommended for use in older patients.</p></div>
<div class="block dop drugH1Div" id="F52812504"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13275" href="/d/html/13275.html" rel="external">see "Ergotamine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a20dedab-b5d3-47dc-87de-20f6c9db2bbe">Vascular headache</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vascular headache: </b>Very limited data available; efficacy results variable; not routinely used: Adolescents: Sublingual: 2 mg (1 tablet) under tongue at first sign of migraine, then 2 mg (1 tablet) every 30 minutes as tolerated; maximum dose: 6 mg per 24 hours, or 10 mg/week has been reported in clinical experience (Géraud 2004; Welborn 1997) <b>Note:</b> Not a preferred agent, use of ergotamine has largely been replaced by newer agents with improved efficacy and adverse effect profile.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729705"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with impaired renal function.</p></div>
<div class="block dohp drugH1Div" id="F52729706"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in patients with impaired hepatic function.</p></div>
<div class="block adr drugH1Div" id="F166282"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Bradycardia, cold extremities, ECG changes, edema, hypertension, ischemia, tachycardia, valvular sclerosis, vasospasm</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Numbness, paresthesia, precordial pain, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Gangrene of skin or other tissue, pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Retroperitoneal fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Myalgia, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Cyanosis, pleuropulmonary fibrosis</p></div>
<div class="block coi drugH1Div" id="F166295"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ergotamine or any component of the formulation; pregnancy or childbearing potential; peripheral vascular disease; hepatic or renal impairment; coronary artery disease; hypertension; sepsis; ergot alkaloids are contraindicated with strong inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F166279"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac valvular fibrosis: Ergot alkaloids have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Vasospasm or vasoconstriction can occur, possibly resulting in decreased cerebral blood flow, ECG changes, and hypertension; sustained vasoconstriction may also lead to ischemic colitis, intermittent claudication, aggravation of angina, or precipitation of MI. Do not use in any patient at risk or predisposed to vascular effects of ergot alkaloids. In a scientific statement from the American Heart Association, ergotamine has been determined to be an agent that may cause direct myocardial toxicity (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ergotism: Ergot alkaloid use may result in ergotism (intense vasoconstriction) resulting in peripheral vascular ischemia and possible gangrene. Ergotism is usually associated with overdosage or prolonged chronic use; do not exceed dosing guidelines and avoid prolonged administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Avoid use in the elderly due to the vasoconstrictive properties and cardiovascular adverse effects associated with ergot alkaloids.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Acute migraine agents (eg, 5-HT<sub>1</sub> agonists, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse (Thorlund 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Discontinuation even after limited use may result in withdrawal symptoms (ie, rebound headache, nausea, vomiting).</p></div>
<div class="block foc drugH1Div" id="F166289"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ergomar: 2 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake, saccharin sodium]</p></div>
<div class="block geq drugH1Div" id="F166275"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323132"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Ergomar Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $85.39</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F166292"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Do not crush sublingual tablets.</p></div>
<div class="block admp drugH1Div" id="F52612711"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Sublingual: Place tablet under the tongue; do not crush; may administer without regard to meals. </p></div>
<div class="block use drugH1Div" id="F166291"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Migraine, moderate to severe, acute treatment: </b>Treatment of migraine.</p></div>
<div class="block mst drugH1Div" id="F56411536"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F166339"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F166284"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha1-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Ergot Derivatives may enhance the adverse/toxic effect of Bromocriptine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dihydroergotamine: Ergot Derivatives may enhance the vasoconstricting effect of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the adverse/toxic effect of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: Ergot Derivatives may enhance the vasoconstricting effect of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may diminish the vasodilatory effect of Nitroglycerin. Nitroglycerin may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).  Management: Avoid the use of ergot derivatives in patients receiving nitroglycerin for angina (or in any angina patient) if possible. If combined, monitor for decreased effects of nitroglycerin and increased adverse effects of the ergot derivative (eg, ergotism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the adverse/toxic effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxithromycin: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F166306"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may cause increased blood levels of ergotamine, leading to increased toxicity. Management: Monitor for increased effects/toxicity with concomitant use.</p></div>
<div class="block pri drugH1Div" id="F166297"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ergotamine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Ergotamine may cause prolonged constriction of the uterine vessels and/or increased myometrial tone leading to reduced placental blood flow. This has contributed to fetal growth retardation in animals. Limited human data support the potential for ergotamine to contribute to major congenital malformations and other adverse pregnancy outcomes (Acs 2006; Bánhidy 2007; Medveczky 2004; Raymond 1995; Smets 2004).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of preeclampsia may be increased in patients with migraine (ACOG 2022). Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). When treatment for acute migraine in pregnancy is needed, other agents are recommended. Use of ergotamine is contraindicated for the treatment of migraine during pregnancy (ACOG 2022; CHS [Worthington 2013]).</p></div>
<div class="block brc drugH1Div" id="F166298"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ergotamine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Milk production may be reduced by ergot alkaloids. In addition, toxicity may occur in the mother and infant (Anderson 2019). Exposure to ergotamine via breast milk may cause vomiting, diarrhea, weak pulse, and unstable BP in the breastfed infant.</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment for migraine headaches in lactating patients should be individualized (AHS [Ailani 2021]). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. Use of ergot alkaloids is not recommended for the treatment of migraine in lactating patients (ACOG 2022; Anderson 2019; WHO 2002). Infants exposed to ergotamine via breast milk should be monitored for side effects (WHO 2002).</p></div>
<div class="block pha drugH1Div" id="F166278"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha-adrenergic receptors depending upon their site; is a highly active uterine stimulant; it causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers</p></div>
<div class="block phk drugH1Div" id="F166294"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral, rectal: Erratic (Perrin 1985)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Adults: 1.85 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic, including high first-pass metabolism (Perrin 1985)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral, rectal: ≤5% (Perrin 1985) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 2-2.5 hours (Perrin 1985) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: 2 hours (Perrin 1985)  </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (90%, primarily as metabolites) (Perrin 1985) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F166299"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ergo-Kranit Migraene</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Exmigrex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lingraine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lingraine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ergotamine tartrate nichiiko</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ergo-Kranit Migraene</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ergotam</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Avamigran</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ergomar</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ergomine | Ergosia | Ergotamine | Erraga</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ergonagen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16647835">
<a name="16647835"></a>Acs N, Bánhidy F, Puhó E, Czeizel AE. A possible dose-dependent teratogenic effect of ergotamine. <i>Reprod Toxicol.</i> 2006;22(3):551-552. doi:10.1016/j.reprotox.2006.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/16647835/pubmed" id="16647835" target="_blank">16647835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol.</i> 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31347910">
<a name="31347910"></a>Anderson PO. Migraine drug therapy during breastfeeding. <i>Breastfeed Med.</i> 2019;14(7):445-447. doi:10.1089/bfm.2019.0154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/31347910/pubmed" id="31347910" target="_blank">31347910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506783">
<a name="17506783"></a>Bánhidy F, Acs N, Puhó E, Czeizel AE. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. <i>Br J Clin Pharmacol.</i> 2007;64(4):510-516. doi:10.1111/j.1365-2125.2007.02901.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/17506783/pubmed" id="17506783" target="_blank">17506783</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Edwards WM. Accidental Poisoning of Newborn Infants With Ergonovine Maleate. A Lesson Application To All Delivery Rooms. <i>Clin Pediatr (Phila)</i>. 1971;10(5):257-260.</div>
</li>
<li>
<div class="reference">
                  Ergomar (ergotamine) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15476911">
<a name="15476911"></a>Géraud G, Lantéri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. <i>Clin Ther</i>. 2004;26(8):1305-1318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/15476911/pubmed" id="15476911" target="_blank">15476911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15269928">
<a name="15269928"></a>Medveczky E, Puhó E, Czeizel EA. The use of drugs in mothers of offspring with neural-tube defects. <i>Pharmacoepidemiol Drug Saf.</i> 2004;13(7):443-455. doi:10.1002/pds.900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/15269928/pubmed" id="15269928" target="_blank">15269928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7088766">
<a name="7088766"></a>Orton DA, Richardson RJ. Ergotamine Absorption and Toxicity. <i>Postgrad Med J</i>. 1982;58(675):6-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/7088766/pubmed" id="7088766" target="_blank">7088766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3899452">
<a name="3899452"></a>Perrin VL. Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache. <i>Clin Pharmacokinetics</i>. 1985;10(4):334-352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/3899452/pubmed" id="3899452" target="_blank">3899452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7482356">
<a name="7482356"></a>Raymond GV. Teratogen update: ergot and ergotamine. <i>Teratology</i>. 1995;51(5):344-347. doi:10.1002/tera.1420510511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/7482356/pubmed" id="7482356" target="_blank">7482356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15224717">
<a name="15224717"></a>Smets K, Zecic A, Willems J. Ergotamine as a possible cause of Möbius sequence: additional clinical observation. <i>J Child Neurol</i>. 2004;19(5):398. doi:10.1177/088307380401900518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/15224717/pubmed" id="15224717" target="_blank">15224717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign Against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10611116">
<a name="10611116"></a>Tfelt-Hansen P, Saxena PR, Dahlöf C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. <i>Brain</i>. 2000;123(Pt 1):9-18. doi:10.1093/brain/123.1.9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/10611116/pubmed" id="10611116" target="_blank">10611116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27882516">
<a name="27882516"></a>Thorlund K, Sun-Edelstein C, Druyts E, et al. Risk of medication overuse headache across classes of treatments for acute migraine. <i>J Headache Pain</i>. 2016;17(1):107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/27882516/pubmed" id="27882516" target="_blank">27882516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9255136">
<a name="9255136"></a>Welborn CA. Pediatric migraine. <i>Emerg Med Clin North Am</i>. 1997;15(3):625-636.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/9255136/pubmed" id="9255136" target="_blank">9255136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication: recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. World Health Organization. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5)(suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ergotamine-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9416 Version 229.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
